fda compounded tirzepatide warning 2024 2025 September 2, 2025: U.S. compounding restrictions have stemmed a flood of semaglutide and – Partnership for Safe Medicines FDA issued 25 warning letters

Clinical trials demonstrate that tirzepatide produces greater HbA1c reductions and weight loss compared to semaglutide 1 mg, suggesting the additional GIP receptor agonism provides enhanced metabolic benefits

This mismatch between what the digestive system is doing and what the nervous system anticipates triggers nausea signals through the vagus nerve and brainstem emetic centers

But for all its positives (of which there are a lot, BTW), the drug does come with some negatives, such as nausea

Ferret islet amyloid polypeptide (IAPP): characterization of in vitro and in vivo amyloidogenicity

Who Can Benefit from Tirzepatide Treatment